The ProShares Pet Care ETF tracks the FactSet Pet Care Index, a tier-weighted benchmark of global companies whose business depends on pet ownership. Rather than a broad market fund, this is a concentrated thematic vehicle spanning animal health, pet food, retail, insurance, and supplies. The fund carries a 0.50% expense ratio and is structured as a non-diversified ETF, meaning a limited number of holdings dominate performance.
Top positions reflect this concentration. CHWY (online pet retail), ZTS (animal health pharmaceuticals), IDXX (veterinary diagnostics), and FRPT (fresh pet food) together account for roughly 40% of assets. Other notable names include pet insurer TRUP, diversified healthcare giant MRK, and absorbents producer ODC.
By sector, healthcare (animal pharma, diagnostics, and services) is the largest sleeve at more than 40%, followed by consumer cyclical and consumer defensive categories linked to retail and packaged pet food. Geographically, the portfolio is roughly two-thirds U.S. exposure, with meaningful weight in the United Kingdom, France, Switzerland, and Canada through holdings such as Virbac, Nestlé, Pets at Home Group, and CVS Group. This mix means the ETF's portfolio exposure blends defensive, recurring veterinary revenue with more cyclical, spending-driven consumer businesses — a balance that will shape its future outlook. I also checked this using Tickeron’s AI Screener to see how the holdings compare to others in the industry.
Several developments could influence the fund's trajectory over the coming quarters:
The macro outlook for this fund hinges on the intersection of healthcare resilience and consumer cyclicality. Animal health tends to be more defensive than human discretionary spending because pets still require medical care even during economic softness; diagnostics and pharmaceuticals generate recurring revenue tied to the veterinary visit cycle. This lends the healthcare-heavy portion of the portfolio relative stability.
The consumer-facing portion is more exposed to market trends in discretionary spending. Pet humanization has supported long-term premiumization — owners trading up to higher-quality food and expanded services — but this theme can pause when household budgets tighten. Interest rates matter doubly here: they shape consumer affordability and influence the valuations of growth-oriented names in the portfolio.
On the flow side, the fund has experienced sustained net redemptions, leaving AUM in the low tens of millions of dollars. Smaller asset bases can translate into wider bid-ask spreads and lower trading liquidity, a structural consideration for investors weighing entry and exit. A stabilization or rebound in pet-focused investing sentiment would be a meaningful positive for the fund's scalability and appeal. From what I see, monitoring these flows closely helps clarify whether the structure can support broader adoption.
The most durable driver behind this ETF is the structural growth of pet ownership and the humanization of pets. Households increasingly treat pets as family members, supporting higher spending on premium nutrition, diagnostics, pharmaceuticals, and services. This is a demographic and lifestyle trend that has historically persisted through economic cycles, including recessions.
Technology adoption also plays a role. The growth of e-commerce pet retail, telemedicine in veterinary care, and advanced diagnostics supports the innovation-oriented holdings in the portfolio. Meanwhile, the expansion of pet insurance in underpenetrated markets such as the United States could structurally lift veterinary utilization over time. I’m watching this closely as it could provide additional support for several holdings.
Counterbalancing these tailwinds are structural risks: a concentrated, non-diversified portfolio amplifies single-stock effects, and modest fund size limits liquidity and institutional capacity. The long-term outlook therefore depends on whether secular demand growth can overcome cyclical consumer softness and ongoing redemption pressure. Investors should weigh these structural trends against the fund's inherent concentration when evaluating its future path.
In my research process, I occasionally reference Tickeron’s AI Trend Prediction Engine to review potential directional signals for thematic funds like this one. It offers a structured way to explore forecasts and complements the fundamental review of holdings and macro factors. This kind of tool can help surface additional context without replacing core analysis.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
The Stochastic Oscillator for PAWZ moved out of overbought territory on November 16, 2026. This could be a bearish sign for the stock and investors may want to consider selling or taking a defensive position. A.I.dvisor looked at 65 similar instances where the indicator exited the overbought zone. In 57 of the 65 cases the stock moved lower. This puts the odds of a downward move at 88%.
The 10-day RSI Indicator for PAWZ moved out of overbought territory on November 10, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 22 similar instances where the indicator moved out of overbought territory. In 17 of the 22 cases, the stock moved lower in the following days. This puts the odds of a move lower at 77%.
The Moving Average Convergence Divergence Histogram (MACD) for PAWZ turned negative on November 17, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 41 similar instances when the indicator turned negative. In 35 of the 41 cases the stock turned lower in the days that followed. This puts the odds of success at 85%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PAWZ declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
PAWZ broke above its upper Bollinger Band on November 02, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
PAWZ moved above its 50-day moving average on October 15, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for PAWZ crossed bullishly above the 50-day moving average on October 22, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 18 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 61%.
Following a +5.20% 3-day Advance, the price is estimated to grow further. Considering data from situations where PAWZ advanced for three days, in 227 of 299 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
The Aroon Indicator entered an Uptrend today. In 158 of 229 cases where PAWZ Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 69%.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows